Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford Pharmacology tops QS world rankings

Awards and Appointments General Research

The Department of Pharmacology is delighted to be placed at the top of the world rankings for Pharmacy and Pharmacology according to league tables published this week by QS.

None

The QS World University Rankings by Subject comprise the biggest compilation of international data on higher education ever published. Indicators used to create the rankings include the survey results from 83,000 academics from across the world as well the opinions of 43,000 international graduate recruiters. Research strength is assessed via citations and the H-index of the Department’s researchers.

Read more (Department of Pharmacology website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

NCITA Publishes Comment Article in the British Journal of Cancer

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.